WallStreetZenWallStreetZen

NASDAQ: CNTB
Connect Biopharma Holdings Ltd Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for CNTB

Based on 3 analysts offering 12 month price targets for Connect Biopharma Holdings Ltd

Min Forecast
$7.00+224.07%
Avg Forecast
$8.67+301.25%
Max Forecast
$10.00+362.96%

Should I buy or sell CNTB stock?

Based on 3 analysts offering ratings for Connect Biopharma Holdings Ltd.

Strong Buy
Strong Buy
2 analysts 66.67%
Buy
1 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although CNTB's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates CNTB as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their CNTB stock forecasts and price targets.

CNTB stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-12-01
lockedlocked$00.00+00.00%2025-11-13
lockedlocked$00.00+00.00%2025-08-13

1 of 1

Forecast return on equity

Is CNTB forecast to generate an efficient return?

Company
-51.49%
Industry
355.6%
Market
208.52%
CNTB's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CNTB forecast to generate an efficient return on assets?

Company
-42.33%
Industry
123.2%
CNTB is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CNTB earnings per share forecast

What is CNTB's earnings per share in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
-$3.92
Avg 2 year Forecast
-$3.50
Avg 3 year Forecast
-$0.79

CNTB revenue forecast

What is CNTB's revenue in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$74.3M
Avg 2 year Forecast
$127.9M
Avg 3 year Forecast
$23.8M

CNTB vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CNTB$2.16$8.67+301.25%Strong Buy
TNYA$0.73$5.33+630.55%Strong Buy
ETHZ$5.59N/AN/A
STRO$13.82$20.00+44.72%Hold
ACOG$5.72$18.00+214.69%Buy
View Top Biotech Stocks

Connect Biopharma Holdings Stock Forecast FAQ

Is Connect Biopharma Holdings Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: CNTB) stock is to Strong Buy CNTB stock.

Out of 3 analysts, 2 (66.67%) are recommending CNTB as a Strong Buy, 1 (33.33%) are recommending CNTB as a Buy, 0 (0%) are recommending CNTB as a Hold, 0 (0%) are recommending CNTB as a Sell, and 0 (0%) are recommending CNTB as a Strong Sell.

If you're new to stock investing, here's how to buy Connect Biopharma Holdings stock.

What is CNTB's earnings growth forecast for 2026-2028?

(NASDAQ: CNTB) Connect Biopharma Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 70.57%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.85%.

Connect Biopharma Holdings's earnings in 2026 is N/A.On average, 7 Wall Street analysts forecast CNTB's earnings for 2026 to be -$219,102,639, with the lowest CNTB earnings forecast at -$401,325,729, and the highest CNTB earnings forecast at -$49,893,885. On average, 5 Wall Street analysts forecast CNTB's earnings for 2027 to be -$195,393,959, with the lowest CNTB earnings forecast at -$377,946,880, and the highest CNTB earnings forecast at -$44,024,016.

In 2028, CNTB is forecast to generate -$43,906,619 in earnings, with the lowest earnings forecast at -$43,828,354 and the highest earnings forecast at -$43,437,030.

What is CNTB's revenue growth forecast for 2026-2028?

(NASDAQ: CNTB) Connect Biopharma Holdings's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 114.46%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.4%.

Connect Biopharma Holdings's revenue in 2026 is N/A.On average, 6 Wall Street analysts forecast CNTB's revenue for 2026 to be $4,154,749,086, with the lowest CNTB revenue forecast at $38,963,407, and the highest CNTB revenue forecast at $8,511,868,889. On average, 5 Wall Street analysts forecast CNTB's revenue for 2027 to be $7,152,295,453, with the lowest CNTB revenue forecast at $38,963,407, and the highest CNTB revenue forecast at $14,683,616,725.

In 2028, CNTB is forecast to generate $1,328,602,890 in revenue, with the lowest revenue forecast at $372,541,011 and the highest revenue forecast at $2,336,151,905.

What is CNTB's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: CNTB) forecast ROA is -42.33%, which is lower than the forecast US Biotechnology industry average of 123.2%.

What is CNTB's Price Target?

According to 3 Wall Street analysts that have issued a 1 year CNTB price target, the average CNTB price target is $8.67, with the highest CNTB stock price forecast at $10.00 and the lowest CNTB stock price forecast at $7.00.

On average, Wall Street analysts predict that Connect Biopharma Holdings's share price could reach $8.67 by Dec 1, 2026. The average Connect Biopharma Holdings stock price prediction forecasts a potential upside of 301.25% from the current CNTB share price of $2.16.

What is CNTB's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: CNTB) Connect Biopharma Holdings's current Earnings Per Share (EPS) is N/A. On average, analysts forecast that CNTB's EPS will be -$3.92 for 2026, with the lowest EPS forecast at -$7.18, and the highest EPS forecast at -$0.89. On average, analysts forecast that CNTB's EPS will be -$3.50 for 2027, with the lowest EPS forecast at -$6.76, and the highest EPS forecast at -$0.79. In 2028, CNTB's EPS is forecast to hit -$0.79 (min: -$0.78, max: -$0.78).

What is CNTB's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: CNTB) forecast ROE is -51.49%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.